Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Intrathecal Methotrexate: A Treatment Option for Patients With Progressive Multiple Sclerosis?
Could intrathecally administered methotrexate be a viable treatment option for your patients with progressive forms of multiple sclerosis?
Could intrathecally administered methotrexate be a viable treatment option for your patients with progressive forms of multiple sclerosis?
Here to discuss the results of a study designed to test the feasibility of this therapeutic approach is neurologist Saud Sadiq. Dr Sadiq is Founder and Director of the International Multiple Sclerosis Management Practice and the Multiple Sclerosis Research Center of New York.
Dr Sadiq and his coauthors published their study in the Journal of Neurology. For the full report, please click here [pdf].
Intrathecal Methotrexate for Patients With MS?
Related Videos
Related Content
